Abstract
Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Current Cancer Therapy Reviews
Title:Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Volume: 12 Issue: 1
Author(s): Diego Touya, Kathrin Strasser-Weippl, Ann Whalen, Jessica St. Louis and Paul Goss
Affiliation:
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Abstract: Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Export Options
About this article
Cite this article as:
Touya Diego, Strasser-Weippl Kathrin, Whalen Ann, Louis St. Jessica and Goss Paul, Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160617081058
DOI https://dx.doi.org/10.2174/1573394712666160617081058 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Breast Cancer: Current Molecular Therapeutic Targets and New Players
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptor: Structural Differences and Potential Implications on Selectivity Examined by the GRID/CPCA Approach
Letters in Drug Design & Discovery Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design A Comprehensive Review on the Medicinal Importance; Biological and Therapeutic Efficacy of <i>Lagenaria siceraria</i> (Mol.) (Bottle Gourd) Standley Fruit
Current Topics in Medicinal Chemistry Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Celiac Disease: Pathogenesis and Novel Therapeutic Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Current Cancer Drug Targets Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery
Current Medicinal Chemistry Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine Fasting Insulin and Risk of Cancer Related Mortality in Non-diabetic Adults: A Dose-response Meta-analysis of Cohort Studies
Current Diabetes Reviews Cyclodextrins for Non-Viral Gene and siRNA Delivery
Pharmaceutical Nanotechnology The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets